Oramed Pharmaceuticals (Nasdaq:ORMP) announced today that it received a new patent for its oral diabetes treatment. The U.S. Patent and Trademark Office (USPTO) granted a patent titled “Methods and Compositions for Treating Diabetes.” This patent extends a patent previously granted in May 2022. According to a news release, the patent addresses methods and compositions for […]
Ypsomed, Mediq complete sale of DiaExpert
Ypsomed and Mediq announced today that they completed the sale of mail-order retailer for diabetes care DiaExpert. Germany-based DiaExpert specializes in insulin pump therapy. The companies previously announced the sale of DiaExpert in October. This sale allows Ypsomed to focus on the manufacture and sale of its own medical technologies. That focus continues to narrow […]
The 10 biggest diabetes tech stories from 2022
2022 represented a landmark year for next-generation diabetes tech. Here are the biggest stories from the past year. Some companies picked up major regulatory nods. Others experienced major regulatory setbacks. Partnerships were formed and ended, while mergers and acquisitions came and went. There were many stories to choose from in the world of diabetes tech, […]
Eyenovia unveils digital ocular drug delivery device
Eyenovia (Nasdaq:EYEN) announced today that it is developing a microdosing system to facilitate the digital delivery of eye medications. New York-based Eyenovia develops a pipeline of late-stage microdose array print (MAP) therapeutics. It aims for this system to improve the overall patient experience and streamline practice flow. The investigational device showed promise in delivery cleaner […]
FDA clearance for Dexcom G7 marks a ‘huge leap’ forward, COO Jake Leach says
After plenty of anticipation — and a bit of waiting — the next-generation Dexcom G7 continuous glucose monitor is finally here. In mid-2021, Dexcom (Nasdaq:DXCM) CEO Kevin Sayer told Drug Delivery Business News that its next-generation CGM would be “wonderful.” At the time, he said enthusiasm over the Dexcom G7 sat at an all-time high. About […]
Abbott FreeStyle Libre 3 links with automated insulin delivery system for use in Europe
Abbott (NYSE:ABT) today announced compatibility between its FreeStyle Libre 3 sensor and the mylife Loop from Ypsomed and CamDiab. Combined, the technologies create a smart, automated process for insulin delivery based on real-time glucose data. The companies launched their automated insulin delivery (AID) system in Germany. They intend to offer it in additional European countries […]
Embecta stock slides on mixed Q4 results
Embecta (Nasdaq:EMBC) shares dipped today on fourth-quarter results that came in mixed compared to the consensus forecast. EEMBC shares fell more than 12% to $29.73 apiece in morning trading. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up more than 4%. The Parsippany, New Jersey-based company posted losses […]
Amalgam Rx, Novo Nordisk expand partnership on connected insulin delivery devices
Amalgam Rx announced today that it expanded its global agreement with Novo Nordisk over the commercialization of Dose Check. Wilmington, Delaware-based Amalgam Rx develops the Dose Check digital insulin initiation and titration app. It designed the app to help people with type 2 diabetes using basal insulin. The two companies partnered to incorporate and integrate […]
Analysts remain neutral on Embecta, await insulin patch pump developments
BTIG analysts maintained their neutral rating for Embecta (Nasdaq:EMBC) ahead of the company’s fourth-quarter earnings report next week. Embecta, the BD diabetes spinoff, reports its fourth-quarter earnings on Tuesday, Dec. 20. Analysts Marie Thibault and Sam Eiber also expect 2023 guidance to come from management then. The analysts mainly expect the patch pump market to […]
Insulet COO announces intent to retire
Insulet (Nasdaq:PODD) issued an SEC filing confirming that Charles Alpuche, executive vice president and chief operating officer, intends to retire. Alpuche informed the company of his decision to retire on Dec. 13. His retirement takes effect on Dec. 31, 2022. The Acton, Massachusetts-based automated insulin delivery technology developer promoted Prem Singh as a result. Singh […]
